Insider buying last 90 days
No open-market insider purchases were filed for AGIO in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every AGIO insider filing, plotted on the chart in Gekko.Open AGIO in Gekko
NASDAQ: AGIO
Agios Pharmaceuticals (AGIO) Stock Analysis & Forecast
Oct 12 close
$30.82−0.99 (−3.1%)
Gekko Brief
AI summaryOct 12 closeThis week brings a mix of analyst commentary and a reminder of recent pipeline setbacks for Agios. RBC Capital maintained a Hold rating with a $32.00 price target, while Truist Financial reiterated a Buy rating and a $37 target, reflecting divided views among analysts. Separately, coverage noted that AGIO shares have dropped 29% over three months, a decline attributed largely to the discontinuation of pipeline candidate tebapivat across all indications after it failed to show sufficient differentiation, even as mitapivat sales continue. Agios also confirmed it will host its third-quarter 2026 earnings call on November 5.
AGIO closed at $30.82, down 3.1%, sitting between its 50-day average of $33.08 and 200-day average of $31.21, a mixed trend signal. The GekkoIndex reads 66.7, placing the stock in the Accumulation zone. Price sits 11.8% below Gekko Fair Value of $34.96, a gap that bears watching.
Agios reports third-quarter results on 5 November, 24 days away and within a typical 20-trading-day holding window, a factor worth noting for near-term volatility given an average absolute reaction of 4.3% historically. Over the last 90 days, Congressional activity shows 1 buy and 0 sells. Seasonality from this point in the calendar has averaged a 5.4% gain over the next 20 trading days across 5 years, rising in 4 of them. Analyst consensus among 7 firms stands at 5 buy and 2 hold ratings, with a consensus target of $46.00.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Agios Pharmaceuticals price vs fair value
Close $30.82200-day averageGekko Fair Value $34.96
Agios Pharmaceuticals quick facts
- Market cap
- $1.84B
- P/E ratio
- —
- Forward P/E
- 2.5
- EPS, TTM
- −$7.01
- Revenue, TTM
- $98.34M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.63
- Volume
- 647,844 avg 990,589
- 1-year return
- −27.4%
- Typical daily move
- ±4%
- Typical 20-day move
- ±7.9%
- 50-day average
- $33.08
- 200-day average
- $31.21
- Next earnings
- Nov 5 before open
- Shares outstanding
- 59.70M
Agios Pharmaceuticals swing-trade checklist
Agios Pharmaceuticals scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $30.82 sits between the 50-day ($33.08) and 200-day ($31.21) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
66.7, Accumulation
Reading 66.7 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
11.8% below
Price is 11.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+5.4% on average
From this point in the calendar, the next 20 trading days averaged +5.4% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Agios Pharmaceuticals stock chart and price history
Agios Pharmaceuticals closed at $30.82 on Oct 12, 2026, −27.4% over the past year, inside a 52-week range of $22.24 to $46.00.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −8.3%
- 3 months
- −22.8%
- 6 months
- −7.0%
- 1 year
- −27.4%
The full AGIO chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open AGIO in Gekko
Follow Agios Pharmaceuticals through every session
Put AGIO on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track AGIO in GekkoFree for 7 days. No credit card required.
About Agios Pharmaceuticals
Agios Pharmaceuticals works in biopharmaceutical research, with a focus on cellular metabolism and the diseases that stem from it. The company is known for PYRUKYND, a treatment that works by activating pyruvate kinase enzymes, both the normal form and several mutated variants, to help manage hemolytic anemias in patients who need it.
Beyond its marketed treatment, Agios has a pipeline that includes AG-946, a compound still in early Phase I testing aimed at hemolytic anemias and other related conditions. This points to a company built around a research and development cycle, moving candidate therapies through clinical trials toward potential approval, with patients affected by blood disorders tied to metabolic dysfunction as the intended beneficiaries of its work.
Agios was founded in 2007 and runs its main office out of Cambridge, Massachusetts. Its shares trade on the NASDAQ under the ticker AGIO.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- agios.com
Agios Pharmaceuticals GekkoIndex: the smart money zone
Agios Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 66.7, in the Accumulation zone, up 0.9 points over five sessions.
66.7Accumulation
Up 0.9 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 26 | +1.6% | +4.7% | ||
| Accumulation (current zone) | 210 | +1.3% | +4.0% | ||
| Neutral | 382 | 0.0% | +1.9% | ||
| Distribution | 58 | +3.3% | +1.8% | ||
| Selling | 6 | Too few readings yet | |||
Average AGIO share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the AGIO price, zone by zone.Track AGIO in Gekko
Is Agios Pharmaceuticals stock overvalued? Gekko Fair Value
Agios Pharmaceuticals trades 11.8% below Gekko Fair Value of $34.96, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Agios Pharmaceuticals shares are worth, recalculated every trading day.
$34.96
Gekko Fair Value, Oct 10, 2026
11.8% Undervalued
At the end of Aug 2026 the price was 20.3% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open AGIO in Gekko
Agios Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Agios Pharmaceuticals, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Gilbert Cisneros House, CA, purchase | $1,001 - $15,000 | Sep 11 traded Aug 20 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Agios Pharmaceuticals has been buying back its own shares.
- Bought back, quarter ended Dec 31, 2021
- $19.05M
- As a share of market cap
- 1.04%
From company filings.
Agios Pharmaceuticals earnings: next date and track record
Agios Pharmaceuticals reports on Nov 5, 2026, before the open (24 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected before the open, 24 days away
- EPS estimate
- −$1.24
- Revenue estimate
- $51.95M
4 of 8reports beat the EPS estimate
±4.3%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Apr 29, 2026 AI summary
- What they said
- Agios reported strong Q1 2026 execution driven by the U.S. commercial launch of AQVESME in thalassemia and continued pipeline progress. Net revenues for mitapivat were $20.7 million worldwide (U.S. $18.8M; ex-U.S. $1.9M), representing 138% year-over-year growth. The company emphasized a successful REMS-enabled launch with 242 prescriptions written by REMS-certified physicians as of March 31, rapid early conversions among highly motivated patients, and growing geographic breadth of prescribers (majority community hem-oncs). Agios plans to submit an sNDA for mitapivat in sickle cell disease in Q2 under the U.S. accelerated approval pathway and has engaged with the FDA on a confirmatory trial design. Pipeline milestones expected in 2026 include Phase IIb topline data for tebapivat in lower-risk MDS (H1), Phase II tebapivat data in sickle cell (H2), Phase I AG-236 data (H1), and Phase Ib AG-181 proof-of-mechanism data (H2). Financial discipline was emphasized: operating expenses are expected to be approximately flat in 2026 versus 2025, and cash and marketable securities exceed $1 billion. R&D and SG&A increased modestly versus prior year driven by pipeline advancement and commercial launch activity.
- Guidance
- 2026 operating expenses expected to be approximately flat versus 2025. Company expects to file sNDA for mitapivat in sickle cell disease in Q2 2026 under the U.S. accelerated approval pathway. PKD revenue guidance implied by commentary: full-year PKD revenue expected roughly $45M-$50M. Timing guidance for pipeline readouts: Phase IIb tebapivat MDS topline (H1 2026), Phase I AG-236 healthy volunteer topline (H1 2026), Phase II tebapivat sickle cell topline (H2 2026), Phase Ib AG-181 PKU proof-of-mechanism (H2 2026).
- Risks flagged
- Regulatory risk around accelerated approval and confirmatory trial design and execution; competitive risk from other entrants (notably recent competitor data referenced); payer access and timing (policy setup often ~6 months); commercialization execution risk as launch scales beyond early highly motivated patients; clinical development risk for tebapivat and other early-stage programs; higher operating expenses in R&D and SG&A relative to prior year.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Apr 29, 2026 | −$1.69 est −$1.79 | $20.75M est $13.30M | +12.9% |
| Feb 12, 2026 | −$1.85 est −$1.95 | $19.97M est $12.09M | +0.9% |
| Oct 30, 2025 | −$1.78 est −$1.91 | $12.88M est $11.70M | +3.1% |
| Jul 31, 2025 | −$1.93 est −$1.75 | $12.46M est $10.28M | −6.8% |
| May 1, 2025 | −$1.55 est −$1.76 | $8.73M est $9.99M | +1.4% |
| Feb 13, 2025 | −$1.74 est −$1.63 | $10.73M est $9.35M | +1.2% |
| Oct 31, 2024 | −$1.47 est $7.91 | $8.96M est $9.27M | −3.1% |
| Aug 1, 2024 | −$1.69 est −$1.60 | $8.62M est $9.31M | −5.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Agios Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Agios Pharmaceuticals is $46.00, +49.3% from the last close, from 7 firms rating the stock in the last 90 days.
$46.00consensus 12-month target, +49.3% from the last close
Now $30.82Avg $46.00
Low $32High $55
Each firm’s latest rating in the last 90 days: 7 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 8 | RBC Capital | $32 | +3.8% |
| Oct 7 | Truist Financial | $37 | +20.1% |
| Oct 6 | Bank of America Securities | $50 | +62.2% |
| Sep 21 | Bank of America Securities | $50 | +62.2% |
| Aug 11 | Truist Financial | — | — |
+4.0%average 20-day move after past Accumulation readings
+5.4%average move over the next 20 trading days in the last 5 years
±4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Agios Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Agios Pharmaceuticals averaged +5.4% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.2% | 3 of 5 |
| Next 10 trading days | +1.8% | 3 of 5 |
| Next 15 trading days | +4.5% | 4 of 5 |
| Next 20 trading days | +5.4% | 4 of 5 |
| Next 30 trading days | −4.1% | 2 of 5 |
For scale, AGIO’s typical 20-trading-day move in either direction is about 7.9%.
Agios Pharmaceuticals market cap and key statistics
Agios Pharmaceuticals’s market cap is $1.84B and revenue of $98.34M over the last twelve months.
Valuation
- Market cap
- $1.84B
- Forward P/E
- 2.5
- EPS, TTM
- −$7.01
- Gekko Fair Value
- $34.96
Trading
- Volume
- 647,844
- Avg volume, 20 days
- 990,589
- 52-week high
- $46.00
- 52-week low
- $22.24
- Shares outstanding
- 59.70M
Financials
- Revenue, TTM
- $98.34M
- Profit margin
- 0%
- Return on equity
- -34.3%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.63
- Typical daily move
- ±4%
- Typical 20-day move
- ±7.9%
Agios Pharmaceuticals stock news this week
Coverage of Agios Pharmaceuticals this week reads neutral: 1 positive, 4 neutral and 1 negative headlines.
- (AGIO) and the Role of Price-Sensitive AllocationsStock Traders Daily, Oct 10
- Agios Pharma (AGIO) Gets a Hold from RBC CapitalThe Globe and Mail, Oct 10
- Agios Pharmaceuticals, Inc. (AGIO) Stock Price, News, Quote & HistoryYahoo! Finance Canada, Oct 10
- Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ETwww.marketscreener.com, Oct 8
- Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $37Moomoo, Oct 7
- AGIO Stock Sinks 29% in Three Months: Here's What You Need to KnowTradingView, Oct 7
Agios Pharmaceuticals peers
Agios Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Agios Pharmaceuticals stock FAQ
What is Agios Pharmaceuticals’s market cap?
Agios Pharmaceuticals’s market cap is $1.84B at the Oct 12, 2026 close of $30.82, with 59.70M shares outstanding.
What is the Agios Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Agios Pharmaceuticals is $46.00, +49.3% from the last close. Of the 7 firms that rated the stock in the last 90 days, 5 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Agios Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Agios Pharmaceuticals is undervalued: the Oct 12, 2026 close of $30.82 is 11.8% below Gekko Fair Value of $34.96. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Agios Pharmaceuticals report earnings next?
Agios Pharmaceuticals is expected to report on Nov 5, 2026, before the market opens (24 days away). Analysts expect earnings of −$1.24 per share on revenue of $51.95M. Agios Pharmaceuticals beat the earnings estimate in 4 of its last 8 reports, moving 4.3% on average across the report.
What is Agios Pharmaceuticals’s 52-week high and low?
Agios Pharmaceuticals’s 52-week high is $46.00 and its 52-week low is $22.24; it closed at $30.82 on Oct 12, 2026, −27.4% over the past year. Over the last five years the shares peaked at $62.58 on Nov 11, 2024.
Is Agios Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Agios Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.